Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-10-23
2007-10-23
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S317000, C514S563000, C514S593000, C514S604000, C514S870000
Reexamination Certificate
active
11099332
ABSTRACT:
A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATPchannel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATPchannel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NCCa-ATPchannel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.
REFERENCES:
patent: 5047429 (1991-09-01), Nye
patent: 5166162 (1992-11-01), Masereel et al.
patent: 5215985 (1993-06-01), Murphy et al.
patent: 5236932 (1993-08-01), Greenfield et al.
patent: 5281599 (1994-01-01), Murphy et al.
patent: 5451580 (1995-09-01), Murphy et al.
patent: 5545656 (1996-08-01), Loose et al.
patent: 5677344 (1997-10-01), Greenfield et al.
patent: 5849796 (1998-12-01), Gericke et al.
patent: 5929082 (1999-07-01), Chambers et al.
patent: 6056977 (2000-05-01), Bhagwat et al.
patent: 6100047 (2000-08-01), Wilkison et al.
patent: 6187756 (2001-02-01), Lee et al.
patent: 6242200 (2001-06-01), Wilkison et al.
patent: 6372743 (2002-04-01), Darrow et al.
patent: 6492130 (2002-12-01), Wilkison et al.
patent: 6511989 (2003-01-01), Heitsch et al.
patent: 6569633 (2003-05-01), Wilkison et al.
patent: 6569845 (2003-05-01), Futamura et al.
patent: 6596751 (2003-07-01), Fujita et al.
patent: 6610746 (2003-08-01), Fryburg et al.
patent: 6613785 (2003-09-01), Bril et al.
patent: 6679859 (2004-01-01), Keipert et al.
patent: 2001/0003751 (2001-06-01), Terashita et al.
patent: 2001/0016586 (2001-08-01), Guitard et al.
patent: 2002/0013268 (2002-01-01), Fryburg et al.
patent: 2002/0037928 (2002-03-01), Jaen et al.
patent: 2002/0065315 (2002-05-01), Jensen et al.
patent: 2002/0081306 (2002-06-01), Elliott et al.
patent: 2002/0094977 (2002-07-01), Robl et al.
patent: 2003/0216294 (2003-11-01), Fryburg et al.
Apo-Glibenclamide Data Sheet, Medsafe (New Zealand Medicines and Medical Devices Safety Authority), published Jun. 16, 1999.
Planagger et al, 1994. Acta Neurochir [Suppl] 60: 519-520.
Loffler et al, 1998, Naunyn-Schmiedieberg's Arch Pharmacol, 358: 230-237.
Simard et al. 2006. Nature Medicine. 12(4): 433-440.
Gribble, 2003. Diabetologia. 46: 875-891.
Kempski, 2001. Semin Nephol. 21(3): 303-7; Abstract only.
Unterberg et al, 2004. Neuroscience. 129: 1021-1029.
Kaal et al. 2004. Curr Opin Oncol. 16: 593-600.
Weih et al, Stroke, 32: 2029-2032, published Sep. 2001.
Gribble et al (1997. J. Physiol. 504: 35-45).
Proks et al. 2003. European Journal of Pharmacology. 452: 11-19.
Phillips, A., J Pharm Pharmacology 53: 1169-1174, 2001.
Vidal et al. 2005. European Journal of Cancer. 41: 2812-2818.
Ahmad et al., “Mouse cortical collecting duct cells show nonselective cation channel activity and express a gene related to the cGMP-gated rod photoreceptor channel,”Proc. Natl. Acad. Sci. USA, 89: 10262-10266, 1992.
Angel et al., “The binding site for [3H] glibenclamide in the rat cerebral cortex does not recognize K-channel agonists or antagonists other than sulphonylureas,”Fundam. Clin. Pharmacol, 5(2): 107-15, 1991 (abstract only).
Armijo, “Advances in the physiopathology of epilegtogenesis: molecular aspects,”Rev. Neurol., 34(5): 409-29, 2002 (abstract only).
Ballerini, “Glial cells express multiple ATP binding cassette proteins which are involved in ATP release,”Neuroreport, 13(14): 1789-92, 2002 (abstract only).
Baudelet et al., “Evidence for a Neuroprotective Effect of Pyrid-3-yl-sulphonyl-urea in Photochemically Induced Focal Ischaemia in Rats: Magnetic Resonance Imaging Evaluation,”J. Pharm. Pharmacol., 51: 967-970, 1999.
Bevan et al, “Voltage Gasted Ionic Channels in Rat Cultured Astrocytes, Reactive Astrocytes and an Astrocyte-oligodendrocyte Progenitor Cell,” J. Physiol vol. 82, 1987, pp. 327-335.
Champigny et al., “A voltage, calcium, and ATP sensitive non selective cation channel in human colonic tumor cells,”Biochem. Biophys. Res. Commun., 176: 1196-1203, 1991.
Chen et al., “Cat Swelling and a Nonselective Cation Channel Regulated by Internal Ca2+ and ATP in Native Reactive Astrocytes from Adult Rat Brain,”J. Neurosci., 21(17): 6512-6521, 2001.
Chen et al, “Cell Swelling and a Nonselective Cation Channel Regulated by Internal CA2+ and ATP in Native Reactive Astrocytes from Adult Rat Brain,” The Journal of Neuroscience vol. 21, No. 17, Sep. 1, 2001, pp. 6512-6521.
Davies, “Insulin secretagogues,”Curr. Med. Res. Opin. 18 Suppl., 1: ss22-30, 2002 (abstract only).
Gopalakrishnan et al., “Pharmacological characterization of a 1,4-dihydropyridine analogue, 9- (3,4-dichorophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydro-1,8(2H,5H)-acridinedione (A-184209) as a novelK(ATP) channel inhibitor,”Br. J. Pharmacol., 138(2): 393-99, 2003 (abstract only).
Gray et al., “Non-selective cation channel on pancreatic duct cells,”Biochem. Biophys. Acta, 1029:33-42, 1990.
Gribble et al., “Differential selectivity of insulin secretagogues. Mechanisms, clinical implications, and drug interactions,”J. Diabetes Complications, 17(2 Suppl): Nov. 5, 2003 (abstract only).
Gribble et al., “Tissue Specificity of Sulfonylureas: Studies on Cloned Cardiac and B-Cells K-ATP Channels,”Diabetes, 47: 1412-1418, 1998.
Hambrock et al., “Four novel splice variants of sulfonylurea receptor 1,”Am. J. Physiol. Cell Physiol., 283: C587-C598, 2002.
Hernandez-Sanchez et al., “Mice transgenically overexpressing sulfonylurea receptor 1 in forebrain resist seizure induction and excitotoxic neuron death,”PNAS, 98(6): 3549-3554, 2001.
Jarvis et al., “Purinergic Mechanisms in the Nervous System Function and Disease States,” Psychopharmacology: The Fourth Generation of Progress, (Kupfer, David J. et al., Lippincott 2000), found at www.acnp.org/g4/GN401000063/CH.html.
Kimelberg et al., “Astrocytic swelling in traumatic-hypoxic brain injury. Beneficial effects of an inhibitor of anion exchange transport and glutamate uptake in glial cells,”Mol. Chem. Neuropathol., 11(1): 1-31, 1989 (abstract only).
Koch et al., “Mechanism of shrinkage activation of nonselective cation channels in M-1 mouse cortical collecting duct cells,”J. Membr. Biol., 177(3): 231-42, 2000 (abstract only).
Koch et al., “Osmotic shrinkage activates nonselective cation (NSC) channels in various cell types,”J. Membr. Biol., 168(2): 131-39, 1999 (abstract only).
Lauritzen et al., “The potassium channel opener (-)-cromakalim prevents glutamate-induced cell death in hippocampal neurons,”J. Neurochem., 69(4): 1570-79, 1997 (abstract only).
Lee et al., “Direct demonstration of sulphonylurea-sensitive KATP channels on nerve terminals of the rat motor cortex,”Br. J. Pharmacol., 115(3): 385-87, 1995 (abstract only).
Lee et al., “The high-affinity sulphonylurea receptor regulates KATP channels in nerve terminals of the rat motor cortex,”J. Neurochem., 66(6): 2562-71, 1996 (abstract only).
Lee et al., “Upregulation of Phospolipase D in Astrocytes in Response to Transient Forebrain Ischemia,” GLIA vol. 30, 2000, pp. 311-317.
Liu et al., “Tenidap, a novel anti-inflammatory agent, is an opener of the inwardly rectifying K+ channel hKir2.3,”Eur. J. Pharmacol., 435(2-3): 153-60, 2002 (abstract only).
Mest et al., “Glucose-induced insulin secretion is potentiated
Chen Mingkui
Simard J. Marc
Fulbright & Jaworski LLP
Howard Zachary C.
Kemmerer Elizabeth C.
University of Maryland Baltimore
LandOfFree
Methods for treating neural cell swelling does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating neural cell swelling, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating neural cell swelling will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3896356